-- 根據週五深圳證券交易所發布的公告顯示，北京康康醫療（SHE:000788）已獲得中國國家藥品監督管理局批准，上市銷售託法替尼檸檬酸鹽。 該藥物是一種強效的Janus激酶（JAK）抑制劑，主要用於治療慢性自體免疫疾病，包括僵直性脊椎炎、類風濕性關節炎和乾癬性關節炎。 受此消息提振，北京康康醫療股價在午後交易中上漲1%。
Related Articles
Asia
Tokyo Kiraboshi Financial to Sell 5.5 Million Shares
Tokyo Kiraboshi Financial (TYO:7173) will convert all of its First Series Class I preferred shares into common shares and cancel the preferred stock, while conducting a secondary share offering to broaden its shareholder base, according to a Friday filing on the Tokyo Stock Exchange.Sumitomo Mitsui Trust Bank, which holds all 750,000 preferred shares in the company, will request conversion into 5.5 million common shares in two stages. Tokyo Kiraboshi will then cancel all preferred shares after the conversion process is completed.The lender also resolved to conduct a secondary offering of 5.5 million common shares held by Sumitomo Mitsui Trust Bank, alongside a possible over-allotment of up to 824,700 shares.The conversion and sale will result in changes to its major shareholders, Tokyo Kiraboshi said.Sumitomo Mitsui Trust Bank is expected to temporarily become the company's largest shareholder before reducing its stake through the share sale.
$TYO:7173
Asia
Marumae to Sell New Shares, Treasury Stock in Capital Raising Plan
Marumae (TYO:6264) will issue new shares and conduct secondary share offerings to fund semiconductor and FPD production capacity expansion, consumables business investments, and debt repayment tied to its acquisition of KM Aluminum, according to a Friday filing on the Tokyo Stock Exchange.The company plans to issue 2 million new shares and dispose of 700,000 treasury shares through public offerings. It will also conduct secondary offerings totaling up to 1.4 million shares, including an over-allotment option.Marumae expects to use about 2 billion yen for production equipment and capital expenditures in its precision components business by August 2028, while 1.5 billion yen will go toward production equipment and factory renovations for its functional materials business.The remaining proceeds of about 2.35 billion yen will fund repayment of long-term borrowings by August 2027.The company said the offerings will also improve share liquidity and support efforts to meet TOPIX index selection criteria by increasing its free-float ratio.
$TYO:6264
Asia
Tokyo Kiraboshi Financial to Book 43 Billion Yen Dividend Income From Unit
Tokyo Kiraboshi Financial Group (TYO:7173) will receive a 43 billion yen dividend from consolidated subsidiary Kiraboshi Bank, according to a Friday filing on the Tokyo Stock Exchange.The dividend is scheduled to be paid on May 20 and will be recorded as operating income in the company's non-consolidated financial statements for the fiscal year ending March 2027.
$TYO:7173